DFFN · Diffusion Pharmaceuticals Inc

-

Please sign in to comment on DFFN

1 Comment

Admin

4 years ago

Diffusion Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 26.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Diffusion Pharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 8.3% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 39.2% to $-3M since the same quarter in the previous year.

Based on the above factors, Diffusion Pharmaceuticals Inc gets an overall score of 1/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US2537484048
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Target Price	40
Market Cap	9M
Beta	1.76
Dividend Yield	0.0%

ABOUT

Diffusion Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

DFFN · Diffusion Pharmaceuticals Inc

-

Diffusion Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Diffusion Pharmaceuticals Inc using a moving average strategy